Syndax shares soar as lead drug clears a mid-stage cancer drug study hurdle
Briggs Morrison has good reason today to be glad he left the Big Pharma R&D world behind at AstraZeneca and switched to biotech. The CEO …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
